How Copper Transporters Affect Cisplatin Treatment
Author Information
Author(s): Paolo Abada, Stephen B. Howell
Primary Institution: Moores Cancer Center and Department of Medicine, University of California, San Diego
Hypothesis
Copper transporters CTR1 and CTR2 influence the uptake and effectiveness of cisplatin in cancer treatment.
Conclusion
CTR1 enhances cisplatin uptake while CTR2 limits it, suggesting they have opposite roles in the effectiveness of platinum-based drugs.
Supporting Evidence
- CTR1 is essential for the uptake of cisplatin and other platinum drugs.
- Knockout of CTR1 leads to resistance against cisplatin.
- Knockdown of CTR2 increases cisplatin uptake and cytotoxicity.
- CTR2 appears to limit the influx of platinum drugs.
Takeaway
Copper transporters help cells take in or get rid of copper, and they also affect how well a cancer drug called cisplatin works. One transporter helps the drug get in, while the other one tries to keep it out.
Methodology
The study reviews the roles of copper transporters CTR1 and CTR2 in the uptake and cytotoxicity of cisplatin, based on various experimental findings.
Limitations
The evidence regarding CTR2's role in regulating platinum drug accumulation is primarily from one laboratory and requires further verification.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website